No Data
No Data
Regional Bank Performance: Goldman Sachs Breaks Down Q2 2024 Earnings
In a recent analyst note by Goldman Sachs, the outlook for several regional banks were evaluated based on their recent second-quarter 2024 earnings reports. Among the banks examined included KeyCorp (
Check Out What Whales Are Doing With PFE
Investors with a lot of money to spend have taken a bullish stance on Pfizer (NYSE:PFE).And retail traders should know.We noticed this today when the trades showed up on publicly available options
Dividend Roundup: Goldman Sachs, Johnson & Johnson, Qualcomm, Caterpillar, and More
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy.
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
More than half of the states in the U.S. are experiencing significant Covid-19 activity in wastewater, and President Joe Biden remains in isolation after announcing Wednesday he caught the virus for
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
On Wednesday, Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announced that the participants of the Phase 3 VALOR trial have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15.